Identification of potential drugs for treatment of hepatic lipidosis in cats using an in vitro feline liver organoid system.

ABSTRACT: BACKGROUND:Hepatic lipidosis is increasing in incidence in the Western world, with cats being particularly sensitive. When cats stop eating and start utilizing their fat reserves, free fatty acids (FFAs) increase in blood, causing an accumulation of triacylglycerol (TAG) in the liver. OBJECTIVE:Identifying potential new drugs that can be used to treat hepatic lipidosis in cats using a feline hepatic organoid system. ANIMALS:Liver organoids obtained from 6 cats. METHODS:Eight different drugs were tested, and the 2 most promising were further studied using a quantitative TAG assay, lipid droplet staining, and qPCR. RESULTS:Both T863 (a diacylglycerol O-acyltransferase 1 [DGAT1] inhibitor) and 5-aminoimidazole-4-carboxamide 1-?-D-ribofuranoside (AICAR; an adenosine monophosphate kinase activator) decreased TAG accumulation by 55% (P

SUBMITTER: Haaker MW 

PROVIDER: S-EPMC6979087 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature